olmesartan has been researched along with pioglitazone in 5 studies
Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (pioglitazone) | Trials (pioglitazone) | Recent Studies (post-2010) (pioglitazone) |
---|---|---|---|---|---|
841 | 185 | 554 | 4,338 | 824 | 2,277 |
Protein | Taxonomy | olmesartan (IC50) | pioglitazone (IC50) |
---|---|---|---|
CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1 | |
Bile salt export pump | Rattus norvegicus (Norway rat) | 2 | |
Peroxisome proliferator-activated receptor gamma | Rattus norvegicus (Norway rat) | 0.7 | |
Bile salt export pump | Homo sapiens (human) | 0.337 | |
Carbonic anhydrase 2 | Homo sapiens (human) | 0.114 | |
Steryl-sulfatase | Homo sapiens (human) | 0.8 | |
Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 1.15 | |
Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.298 | |
Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 3.0379 | |
Peroxisome proliferator-activated receptor gamma | Mus musculus (house mouse) | 0.7 | |
CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 4.8 | |
CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 8.65 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Gust, R; Obexer, P; Salcher, S; Schoepf, AM | 1 |
Bhaumik, U; Chakraborty, US; Chatterjee, B; Pal, TK; Roy, B; Sarkar, AK; Sengupta, P | 1 |
5 other study(ies) available for olmesartan and pioglitazone
Article | Year |
---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARĪ³ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; PPAR gamma; Structure-Activity Relationship; Telmisartan | 2020 |
Development and validation of an LC-ESI-MS/MS method for simultaneous quantitation of olmesartan and pioglitazone in rat plasma and its pharmacokinetic application.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chromatography, High Pressure Liquid; Imidazoles; Male; Pioglitazone; Rats; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tetrazoles; Thiazolidinediones | 2010 |